{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 61 of 128', '10.4 Lost to follow-up', 'A subject will be considered lost to follow-up if he/she repeatedly fails to return for scheduled', 'visits and if the trial site is not able to get in contact with the subject.', 'The following actions must be taken if a subject fails to return to the trial site for a required', 'visit:', 'The trial site must attempt to contact the subject and reschedule the missed visit as', 'soon as possible to retrieve eDiary and unused IMP and counsel the subject on the', 'importance of maintaining the assigned visit schedule and ascertain whether or not', 'the subject wishes to continue in the trial.', 'Before a subject is deemed lost to follow-up, the investigator or designee must', 'make every effort to regain contact with the subject. Should the subject continue to', 'be unreachable, he/she will be considered as withdrawn from the trial with a', 'primary reason of lost to follow-up.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 62 of 128', '11 Trial assessments and procedures', '11.1 Overview', 'Evaluations to be done at each visit are shown in the schedule of trial procedures in Section 4.', 'Refer to Section 7.1 for further details on the trial design.', 'Assessments and procedures at each trial visit should be performed in the following order as', 'shown in Panel 6:', 'Panel 6: Sequence of assessments', 'Patient-reported outcomes', \"At the screening visit, subject's eligibility to enter the trial has to\", 'be confirmed before the PROs can be completed', 'Efficacy assessments by the investigator', 'Safety assessments by the investigator', 'Subject assessment of local tolerability', 'Laboratory and other assessments*', '* Blood sampling for PK and filaggrin mutational status, skin swabs, skin barrier function', 'assessments (selected sites), skin biopsies (optional) and photography of biopsied areas', '(recommended).']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 63 of 128', 'Subjects participating in the trial will be under careful supervision of a principal investigator,', 'who must be a dermatologist or allergist. Investigators must be experienced in treating', 'chronic hand eczema and have documented experience and/or training in use of the', \"assessments required by the protocol and must be either a physician, certified physician's\", 'assistant, or advanced registered nurse practitioner.', 'Whenever possible, the same investigator should perform all the evaluations for a given', 'subject throughout the entire trial period to reduce inter-rater variability.', 'AEs must be assessed by medically qualified personnel (i.e., adequately trained medical', 'doctors) (Section 13.2).', '11.2 Assessments performed only at screening/baseline', '11.2.1 Demographics', 'The following demographic data will be recorded:', 'Date of birth. If full date of birth is not allowed to be recorded, month and year of', \"birth should be collected together with the subject's age.\", 'Sex: female, male.', 'Race: American Indian or Alaska native, Asian, black or African American, native', 'Hawaiian or other Pacific islander, white, other (requires a specification to be', 'provided).', 'Ethnic origin (self-reported by the subject): Hispanic or Latino, not Hispanic or', 'Latino.']\n\n###\n\n", "completion": "END"}